Shruti Pathak

[CRSF - Cancer Research and Statistic Foundation @CRSF_IN]

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

Live streaming for ASCO members available at:
https://t.co/42ztnRihmk

#proudmoment #india #ASCO #medtwitter #cancerresearch

[Dr (Prof). Vijay Patil @DrVijayPatil11]

some snapshot of discussion at NMT&PB

[Dr (Prof). Vijay Patil @DrVijayPatil11]

It might be only time that we have received a letter from JCO congratulating our this paper as it was discussed a lot on social media. Interest generated suggests that this would get adapted in practice. @Amolpatel_dr @oncology_bg @ecancer @VanitaNoronha https://t.co/za2bJ5WjKg

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Very Happy 🎉🎉 to share that low dose immunotherapy full text is published in JCO. @JCO_ASCO @VanitaNoronha @Nandinimenon18 @Amolpatel_dr @SuyogCancer @tmhmedoncalumni @oncology_bg Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study . https://t.co/ZxLV9tSeRo

[Priyanka Bhagyavant @PriaBhagyavant]

Outstanding work by Dr. Vijay & team
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study https://t.co/X3FuHbcEYM @DrVijayPatil11 @VanitaNoronha @Nandinimenon18 @ZoyaPeelay @Shru375 @ShwetaJogdhank1 @Riddhi1321 @SachinDhumal999 @docameya @TataMemorial @RahulKrRai86

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

Proud to share this, led by @DrVijayPatil11 and Dr. Kumar Prabhash. Effective low cost therapy accessible for almost all pts with #HNSCC. #HNCSM @OncoAlert @TataMemorial @tmhmedoncalumni
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study https://t.co/qzU6OIQ0w2

[Bharat @Bhosale26Bharat]

On auspicious occasion of Navaratri important MOU between TMH and Nana Palkar Smruti Samiti.Cancer patients will get benefited in western suburbs of Mumbai with starting 1st chemo day care in collaboration with Sunrise Onco centre Borivali.⁩⁦@TataMemorial⁩⁦

[Dr.Avinash D Talele @DrTaleleAvinash]

Heartiest congratulations and Best wishes, to the team of sunrise onco care, Thank you for bringing the state of art facility along with Best doctors together.

[Bharat @Bhosale26Bharat]

Patil saheb proud of you 👏 congratulations 👏 ICON oration

[Bharat @Bhosale26Bharat]

ImmunoACT CAR-T Facility at Rabale Navi Mumbai . ⁦@DrVijayPatil11⁩ ⁦@ActImmuno⁩ ⁦@purwarrahul2⁩ ⁦@SunriseOncoCare⁩

[Bharat @Bhosale26Bharat]

We are starting our first own chemotherapy day care. My dear friend Dr Ashay and Dr Vijay Sharnangat will look after this centre in western suburbs ( Borivali ). Need your blessings as always. 🙏🙏🙏🙏🙏⁦@SunriseOncoCare⁩

[Shruti Pathak @Shru375]

@Bhosale26Bharat @SunriseOncoCare Many many congratulations 🎉

[Dr. Ashish Gulia @docgulia]

State of art dept of radiotherapy @hbchrc, punjab will cater to 6 states in northern part of India.

[Shruti Pathak @Shru375]

@DrVijayPatil11 @drakhilkapoor1 @DrGunjesh @Nandinimenon18 @SuyogCancer @Amolpatel_dr @Bhosale26Bharat @ashayoncology Thank you so much sir for such great opportunity and support.

[Dr (Prof). Vijay Patil @DrVijayPatil11]

You deserved it. This combination of Paclitaxel Carboplatin TMC has the potential to Trump DCF. It is well tolerated and seems to have better efficacy. @drakhilkapoor1 @DrGunjesh @Nandinimenon18 @SuyogCancer @Amolpatel_dr @Bhosale26Bharat @ashayoncology

[Shruti Pathak @Shru375]

Paclitaxel plus Carboplatin with OMCT as NACT in LAHNSCC. ASCO 2022, Poster board number #22
@DrVijayPatil11 @VanitaNoronha @Nandinimenon18 @ZoyaPeelay

Utterly grateful to Dr Vijay Patil Sir @DrVijayPatil11 for this once in a lifetime opportunity.

[Shruti Pathak @Shru375]

@Nandinimenon18 @DrVijayPatil11 @VanitaNoronha @rakesh_jalali @Bhosale26Bharat @chatterji08 @ZoyaPeelay Many congratulations ma'am.

[Nandini Menon @Nandinimenon18]

Mebendazole in Recurrent Glioblastoma- Results from a Phase 2 Study. Poster board 367 today from 8-11 AM.
@DrVijayPatil11 @VanitaNoronha @rakesh_jalali @Bhosale26Bharat @chatterji08 @ZoyaPeelay
In patients with ECOG PS 0-1, CCNU-MBZ 9-month OS 57.9%

[Dr (Prof). Vijay Patil @DrVijayPatil11]

#ASCO2022 Presentations from TMH focussing on metronomic, low dose immunotherapy and solutions for LMIC. @VanitaNoronha @Nandinimenon18 @H_N_C_I_G @SunilRChopade @Shru375 @tmhmedoncalumni @CancerCrsf @CRSTonline @ATOM_Coalition @GlopesMd @DrEzraCohen @AnticancerOrgUK

[Saurabh Gupta @SKGUPTA_94]

Glad to share my first Ph.D. paper where we aimed to bring Withaferin-A one step closure to clinics by establishing it's toxicity and pharmacokinetics.
Kudos to @GotaVikram and the Clinical Pharmacology group from @ACTREC_TMC to achieve this milestone.
https://t.co/ho4Z8xBdmQ